| Dr Brian James Albiero, DC | |
|
104 Crestview Dr, Suite 202, Bigfork, MT 59911-3558 | |
| (406) 837-3966 | |
| (406) 837-3967 |
| Full Name | Dr Brian James Albiero |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 18 Years |
| Location | 104 Crestview Dr, Bigfork, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790967065 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 1149 (Montana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Albiero Chiropractic Pc | 9739258898 | 2 |
News Archive
USA Today: "In a backlash against President Obama's health care legislation that stretches from Virginia to California, lawmakers in more than two-thirds of the states are scrambling to undercut the bill before it even passes Congress." Legal scholars say that state legislation isn't the final word, however. "The state measures are likely to be challenged in court, setting up new legal battles over whether federal law can trump state laws.
On Jan. 14 at 8:43 p.m., Patrick McKenzie tweeted a plea for tech engineers to help him set up a website to track covid-19 vaccine availability in California. McKenzie, who heads a Bay Area financial services tech company, issued the call to "anyone in California [who] wants to do a civtech project which matters."
Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer.
Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.
Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients.
› Verified 2 days ago
| Provider Name | Albiero Chiropractic Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1457524142 PECOS PAC ID: 9739258898 Enrollment ID: O20080515000722 |
News Archive
USA Today: "In a backlash against President Obama's health care legislation that stretches from Virginia to California, lawmakers in more than two-thirds of the states are scrambling to undercut the bill before it even passes Congress." Legal scholars say that state legislation isn't the final word, however. "The state measures are likely to be challenged in court, setting up new legal battles over whether federal law can trump state laws.
On Jan. 14 at 8:43 p.m., Patrick McKenzie tweeted a plea for tech engineers to help him set up a website to track covid-19 vaccine availability in California. McKenzie, who heads a Bay Area financial services tech company, issued the call to "anyone in California [who] wants to do a civtech project which matters."
Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer.
Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.
Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian James Albiero, DC Po Box 489, Bigfork, MT 59911-0489 Ph: (406) 837-3966 | Dr Brian James Albiero, DC 104 Crestview Dr, Suite 202, Bigfork, MT 59911-3558 Ph: (406) 837-3966 |
News Archive
USA Today: "In a backlash against President Obama's health care legislation that stretches from Virginia to California, lawmakers in more than two-thirds of the states are scrambling to undercut the bill before it even passes Congress." Legal scholars say that state legislation isn't the final word, however. "The state measures are likely to be challenged in court, setting up new legal battles over whether federal law can trump state laws.
On Jan. 14 at 8:43 p.m., Patrick McKenzie tweeted a plea for tech engineers to help him set up a website to track covid-19 vaccine availability in California. McKenzie, who heads a Bay Area financial services tech company, issued the call to "anyone in California [who] wants to do a civtech project which matters."
Researchers from IMIM (Hospital del Mar Medical Research Institute) have identified a new protein, galectin-1, as a possible therapeutic target for pancreatic cancer.
Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.
Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients.
› Verified 2 days ago
Carlson Chiropractic Of Bigfork Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7935 Mt Highway 35, Suite 202, Bigfork, MT 59911 Phone: 406-837-6881 Fax: 406-837-6962 | |
Dr. Isaac Martel, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 8545 Mt Highway 35, Bigfork, MT 59911 Phone: 406-257-6531 | |
Johnson Chiropractic Center, Inc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 8250 Mt Highway 35, Bigfork, MT 59911 Phone: 406-837-3966 Fax: 406-837-3967 | |
Dr. Delaney J Carlson, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7935 Mt Highway 35, Suite 202, Bigfork, MT 59911 Phone: 406-837-6881 Fax: 406-837-6962 | |
Albiero Chiropractic Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 104 Crestview Dr, Suite 202, Bigfork, MT 59911 Phone: 406-837-3966 Fax: 406-837-3967 | |
Treasure State Chiropractic Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 7935 Mt Highway 35 Ste 201, Bigfork, MT 59911 Phone: 406-420-2811 | |
Bigfork Family Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 8545 Mt Highway 35, Bigfork, MT 59911 Phone: 406-890-0668 |